Nuvaira
Nuvaira is a biotech company, founded in 2008. It has raised $94.0M across 2 rounds, most recently a $15.0M Series F in December 2023.
- Employees
- 51–200
- Founded
- 2008
- Website
- nuvaira.com
- Total Funding
- $94.0M
- Last Round
- $15.0M Series FDec 2023
- Rounds
- 2
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 2 funding rounds and 4 investors for this company. The full record is or through the API.
About
Nuvaira, Inc. develops therapies that aim to improve the lives of the more than 65 million people around the world with obstructive lung disease. Its dNerva Lung Denervation System is a novel, catheter-based system used to treat overactive airway nerves in a procedure called Targeted Lung Denervation. Nuvaira was founded in 2008 to address unmet clinical needs in overactive airway nerves, a common feature of both COPD and asthma, and is a privately held medical device company headquartered in Minneapolis, Minnesota with more than 70 patents issued and pending worldwide.
Summary
It lists 51–200 employees. It has raised $94.0M in total across 2 rounds, most recently a $15.0M Series F round in Dec 2023. Investors include US Venture Partners, Qiming VP and Lightstone Ventures.
Funding History
Dec 2023
Sign up to see all 2 events
Funding: Series E through Series F. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/nuvaira"><img src="https://indexed.vc/api/badge/company/nuvaira" alt="Nuvaira on Indexed.vc" width="260" height="76" /></a>